Aligos Therapeutics Gains Fast Track for HBV Drug
SOUTH SAN FRANCISCO, Calif., April 14, 2026 Aligos Therapeutics, Inc. has announced encouraging progress in its Phase 2 B-SUPREME...
Fast Track designation
Advertisement
FDA Clears First-in-Class Vectorized Antibody ALS Trial With VTx-002
Amsterdam, The Netherlands, and Boston, MA — January 8, 2026 — VectorY Therapeutics announced that the U.S. Food and...
MAIA Board Financing Reinforces Confidence in Phase 3 Cancer Drug
CHICAGO, USA | December 24, 2025 — MAIA Biotechnology, a clinical-stage biopharmaceutical company focused on targeted immuno-oncology, announced that...
FDA Grants Fast Track to AJ201 for Kennedy’s Disease Therapy
TAIPEI, Taiwan – October 23, 2025 AnnJi Pharmaceutical Co., Ltd. (AJ Pharm) announced that the U.S. Food and Drug...
Boston Scientific to Acquire Nalu Medical for Pain Therapy Expansion
Marlborough, MA – October 17, 2025 – Boston Scientific Corporation announced that it has entered into a definitive agreement...
Advertisements
FDA Fast Tracks Enterome’s OncoMimics™ Cancer Immunotherapy EO2463
Paris, France – October 16, 2025 – The U.S. Food and Drug Administration (FDA) has granted Fast Track designation...
FDA Fast-Tracks Blacksmith’s FG-2101, a Novel Antibiotic Targeting LpxC
SAN DIEGO, California, October 13, 2025 – In a major advancement for antimicrobial innovation, Blacksmith Medicines, Inc. announced that...
FDA Grants Fast Track Status to Werewolf Therapeutics’ Cancer Drug
WATERTOWN, Mass., October 8, 2025 — Werewolf Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted...
FDA Grants RMAT Designation to Avobis Bio’s AVB-114 for Crohn’s Perianal Fistulas
Newark, Del., October 3, 2025 – Avobis Bio LLC, a clinical-stage biotechnology company focused on implantable cell therapies, announced...
FDA Grants Fast Track Status to NS-229 for Rare Autoimmune Disease
PARAMUS, NJ, September 9, 2025 — The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to...
Advertisement
